Have you got room for a blue chip or two in your portfolio? If you are, then take a look at the blockbuster blue chip shares listed below.
Here's why they are highly rated:
Image source: Getty Images
ResMed Inc. (ASX: RMD)
The first blue chip share to look at is ResMed. It is one of the world's leading medical device companies.
ResMed's focus is primarily on the sleep treatment market and has a portfolio full of industry-leading solutions for sleep apnoea, insomnia, CPAP, and snoring. These products are available in more than 70 countries worldwide thanks to its direct offices and network of distributors.
Positively, the company invests heavily in its research and development, ensuring it stays ahead of the competition. Which certainly is a good thing given the size of the market. Management estimates that there are ~1 billion people suffering from sleep apnoea worldwide. However, the vast majority of these sufferers have yet to be diagnosed. This gives ResMed a significant runway for growth.
Morgans is positive on ResMed's prospects. It recently retained its add rating and put a price target of $30.09 on its shares. The ResMed share price ended the week at $24.88.
Xero Limited (ASX: XRO)
Another blue chip ASX share to consider buying is Xero. It is a highly rated provider of a cloud-based business and accounting solution to small and medium sized businesses.
Like ResMed, Xero has a very large global market opportunity to grow into over the next decade. In addition to this, it has the opportunity to squeeze more and more revenue out of its users via its burgeoning app ecosystem.
It is due to this app ecosystem that Goldman Sachs believes Xero has a multi-decade runway for strong growth.
In light of this, it will come as no surprise to learn that the broker has a buy rating and $157.00 price target on its shares at present. This compares to the latest Xero share price of $127.20.
